Enhancing KDM5A and TLR activity improves the response to immune checkpoint blockade

Liangliang Wang; Yan Gao; Gao Zhang; Dan Li; Zhenda Wang; Jie Zhang; Leandro C. Hermida; Lei He; Zhisong Wang; Jingwen Si; Shuang Geng; Rizi Ai; Fei Ning; Chaoran Cheng; Haiteng Deng; Dimiter S. Dimitrov; Yan Sun; Yanyi Huang; Dong Wang; Xiaoyu Hu; Zhi Wei; Wei Wang; Xuebin Liao

doi:10.1126/scitranslmed.aax2282

Abstract

This is the authors' abstract. We don't add key points for this paper.

expression and could potentially serve as a marker of response to anti-PD-1 immunotherapy. Furthermore, our results indicated that bifunctional agents that enhance both KDM5A and TLR activity warrant investigation as combination therapies with ICB agents.

Ask about this paper

Answers are grounded in this paper and cite their sources.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Wang et al. (2020) studied this question.

synapsesocial.com/papers/6a0063e610d6befb257768a1 https://doi.org/10.1126/scitranslmed.aax2282

View at Publisher

Ask AI

Bookmark

Share

Enhancing KDM5A and TLR activity improves the response to immune checkpoint blockade

Abstract

Ask about this paper

Discussion

Cite This Study

Enhancing KDM5A and TLR activity improves the response to immune checkpoint blockade

Abstract

Ask about this paper

Discussion

Cite This Study

Keep reading

Keep reading